Mamilli last held the role of Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
For people with relapsed or refractory diffuse large B-cell lymphoma
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Subscribe To Our Newsletter & Stay Updated
